SCI Pharmtech Valuation
| 4119 Stock | TWD 90.60 1.90 2.05% |
At this time, the entity appears to be overvalued. SCI Pharmtech has a current Real Value of NT$79.77 per share. The regular price of the entity is NT$90.6. Our model measures the value of SCI Pharmtech from analyzing the entity fundamentals such as Return On Asset of 0.0077, current valuation of 9.19 B, and Return On Equity of 0.0609 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that SCI Pharmtech's price fluctuation is very steady at this time. Calculation of the real value of SCI Pharmtech is based on 3 months time horizon. Increasing SCI Pharmtech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the SCI stock is determined by what a typical buyer is willing to pay for full or partial control of SCI Pharmtech. Since SCI Pharmtech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of SCI Stock. However, SCI Pharmtech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 90.6 | Real 79.77 | Hype 92.5 | Naive 89.91 |
The intrinsic value of SCI Pharmtech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence SCI Pharmtech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of SCI Pharmtech helps investors to forecast how SCI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of SCI Pharmtech more accurately as focusing exclusively on SCI Pharmtech's fundamentals will not take into account other important factors: SCI Pharmtech Total Value Analysis
SCI Pharmtech is presently anticipated to have takeover price of 9.19 B with market capitalization of 9.59 B, debt of 3.65 M, and cash on hands of 1.01 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the SCI Pharmtech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.19 B | 9.59 B | 3.65 M | 1.01 B |
SCI Pharmtech Investor Information
About 49.0% of the company shares are owned by insiders or employees . The book value of SCI Pharmtech was presently reported as 37.3. The company last dividend was issued on the 23rd of August 2021. SCI Pharmtech had 1000:1125 split on the 19th of July 2023. SCI Pharmtech is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.SCI Pharmtech Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of SCI indicates not a very effective usage of assets in December.SCI Pharmtech Ownership Allocation
SCI Pharmtech shows a total of 95.38 Million outstanding shares. SCI Pharmtech maintains substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the entity is less than the current market value, you may not be able to make money on it.SCI Pharmtech Profitability Analysis
The company reported the revenue of 864.22 M. Net Income was 55.7 M with profit before overhead, payroll, taxes, and interest of 208.09 M.About SCI Pharmtech Valuation
Our relative valuation model uses a comparative analysis of SCI Pharmtech. We calculate exposure to SCI Pharmtech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of SCI Pharmtech's related companies.SCI Pharmtech, Inc. develops, produces, and sells active pharmaceutical ingredients, intermediates, and specialty chemicals in Taiwan. SCI Pharmtech, Inc. was founded in 1987 and is based in Taoyuan City, Taiwan. SCI PHARMTECH operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.
8 Steps to conduct SCI Pharmtech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates SCI Pharmtech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct SCI Pharmtech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain SCI Pharmtech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine SCI Pharmtech's revenue streams: Identify SCI Pharmtech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research SCI Pharmtech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish SCI Pharmtech's growth potential: Evaluate SCI Pharmtech's management, business model, and growth potential.
- Determine SCI Pharmtech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate SCI Pharmtech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for SCI Stock Analysis
When running SCI Pharmtech's price analysis, check to measure SCI Pharmtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SCI Pharmtech is operating at the current time. Most of SCI Pharmtech's value examination focuses on studying past and present price action to predict the probability of SCI Pharmtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SCI Pharmtech's price. Additionally, you may evaluate how the addition of SCI Pharmtech to your portfolios can decrease your overall portfolio volatility.